Related Experiment Video
Updated: Jul 5, 2025

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors
Published on: September 14, 2019
Induced pluripotent stem cell (iPSC) line MLi005-A derived from a patient with dominant dystrophic epidermolysis
Sandra Ropret1, Preeti Khurana2, Tara Fabčič1
1Medical Center for Molecular Biology, Faculty of Medicine, University of Ljubljana, Slovenia.
Abstract:
We have generated MLi005-A, a new induced pluripotent stem cell (iPSC) line derived from skin fibroblasts of a male patient with dominant dystrophic epidermolysis bullosa (DDEB). This iPSC line may be used as a model system for studies on skin integrity, the extracellular matrix and skin barrier function. The characterization of the MLi005-A cell line consisted of molecular karyotyping, next-generation sequencing of the COL7A1 alleles, pluripotency and differentiation potentials testing by immunofluorescence of associated markers in vitro. The MLi-005A line has been also tested for ability to differentiate into fibroblasts and keratinocytes and markers associated with these cell types.
Related Concept Videos
Clinical Applications of Epidermal Stem Cells
EPS and iPS Cells in Disease Research
iPS Cell Differentiation
Renewal of Skin Epidermal Stem Cells
Induced Pluripotent Stem Cells

